The SPAC appetite for biotech is not abating, reports Fierce Biotech. This week alone, Foresite Capital’s second SPAC raised $175 million in its IPO, while two other biotech SPACs— European Biotech Acquisition and Frontier Acquisition — filed to raise a total of $300 million in their Nasdaq debuts.
The news comes the same week that Humacyte, a regenerative tissue developer, would go public via a SPAC and two weeks after 23andMe did the same by combining with Richard Branson’s Virgin Group. Read more.
